SCA

ResolveLeather

If any new businesses are being generated. Its business being built in the US because the product isnt tangible but creating a US business can avoid the Tarrif. Kinda like Sony with SCA. It has an American company and can print disks in America. They don't have to worry about Tarrifs because it's American company with a majority foreign shareholders.

Cruian

That doesn't make Standard Charter a frontier market company though. Their HQ being in the UK makes SCA a developed market company even though they operate in frontier markets.

BallerrShotCaller

You were Prior to the merger! That is fantastic! I imagine you know 180LS pretty good! Im going with you bro since Jan long term All-In to 2025+ SCA's are King! Lancet Oct! Finally now we gonna get paid!

InvestorCoast

Check out ATNF if looking for Cannabis Biotech plays (read brief bio below of one of its co-founders Rafael Mechoulam) In addition to upcoming Dupuytren's Phase 3 trial results ($5B addressable market, no current treatment) & beginning final phase of Frozen Shoulder Fibrosis Trial... in the cannabis related platform: Mechoulam and his team are years and years ahead of anyone else in the cannabis related field. And an SCA is required to make the chemical in CBD strong enough to have any real pharmacological use...this is a synthetic analog of the chemical that is created so the strength can then be magnified to a power strong enough for therapeutic value. Mechoulam discovered the body’s endo cannabinoid system, 1st to isolate/ discover THC, recently become only person to formulate synthetic cannabadiol CBD analogs... and is a potential 2021 Nobel (Medical Science) Winner. ATNF’s 3rd platform is based on his patents. He and equally brilliant, Sir Marc Feldman who discovered the current top selling class of drugs... Anti-TNF Biologics (ie Remicade, Humira), are developing a new class of drugs (addressable market expected to be $150B by 2025) to replace current Anti-TNF drugs for Arthritis & other Autoimmune conditions (without the risk profile of current Bioilogics).

Top_Manufacturer_375

Dude they’re not just in the board they’re the ones getting the trials grant funded so they do t need a bunch of employees when grad students and post grads work for free. ATNF is an excellent investment. The founders pioneered blockbuster anti inflammatory drugs Remicade and Humira. Primary Active ingredient for Duputrens Contracture is same drug already approved for another indication— Rheumatoid Arthritis the single largest market in pharmaceuticals. Read that last sentence again the founders discovered the biology behind anti TNF and are world famous academics including a winner of The Lasker Prize. Because the research was done on this P2B/ P3 on diseased human dupuytrens tissue the move straight to FDA drug submission upon proof of concept. Other indications being targeted in future in order are Frozen shoulder, POST Operative Cognitive Decline, Non Alcoholic Stereopathic Hepatitis ( Fatty Liver Disease) and Ulcerative Colitis brought on by smoking cessation. Together all these markets are as big as the Rheumatoid Arthritis market and each of these disorders are caused by inflammation which the founders have pioneered effective biological no surgical treatments. There are no alternative treatments for these conditions. Another pathway being targeted is pain and inflammation using SCA’s— synthetic cannabinol diet analogues. You see a founder is the Israeli scientist who first isolated THC and discovered the human endocanniboid system. Known as godfather of cannabis. Some of you apes might be familiar with the stuff. But it’s synthetic and pure now think about pairing pain relief for musculoskeletal pain with the anti TNF meds proven effective on rheumatoid arthritis and consider that market. Get the picture. Now the CEO has a history of allowing data on patented medication to be released in academic setting. By the way current patents are worth more than stock price. So the catalyst of a keynote address at Oxford to the royal society of hand surgeons is the very stage for release if data. Oxford is also home to founder Sir Ralph Winner of Lasker prize. So do you think Anyone at FDA is denying a NDA for a medication already wildly successful for new indications for which there are no treatments. I don’t think so. It’s like telling Einstein E=MC squared is wrong. There is no one at FDA who can challenge the science. That’s why I bought you do your own DD I like the stock and did I mention it’s a small float and will absolutely explode on news? There’s that too

PolinaDefi

did you see scaleswap unlocked part of SCA token? Hurry up to buy it dip :)

PolinaDefi

did you see scaleswap unlocked part of SCA token? Hurry up to buy it dip :)

PolinaDefi

did you see scaleswap unlocked part of SCA token? Hurry up to buy it dip :)

sammysburner

separately from the SCA? poor bastard.

AdministrativeRub235

WASHINGTON: The small US manufacturers that rushed to produce face masks over the past year are now stuck with hundreds of millions of unsold face coverings because China is flooding the market with below-cost masks, and most may not survive the end of the pandemic. (Puts on MMM?) CAIRO: The Suez Canal Authority (SCA) plans to expand and deepen the southern stretch of the waterway where a container ship became jammed and blocked traffic for six days in March, chairman Osama Rabie said in a televised address on Tuesday (May 11). (Calls on CAT?)

SecessioPlebist

Sadly, the SCA is nationalized, in case anyone was wondering. I was trying to figure out how to short them last night and failed.

Bartins

https://www.reuters.com/article/us-egypt-suezcanal-ship-insurance-idUKKBN2BG31A? Possibly a play here if you can find out who the ship's insurer is. >The ship’s owner, Japanese firm Shoei Kisen KK, and its insurers could face claims from the SCA for loss of revenue and from other ships whose passage has been disrupted, insurers and brokers said. >Container ships of this size are likely insured for hull and machinery damage of $100-140 million, insurance sources say. The ship was insured in the Japanese market, two of the sources said. Could be an enormous payout if forced to pay claims on literally every ship that's delayed plus other damages. My knowledge of Japanese ship insurers is literally zero and the odds of it being traded on an American exchange are similarly low, but an outside shot I suppose. Although if it's true that the Suez Canal Authority provides a pilot to all ships transiting the canal I feel like that puts the pilot and the SCA at fault, but I'm certainly not a maritime law expert.

GrumpyCornell

SCA myself but the knowledge checks out.

splat-y-chila

I'm 95% convinced it's SCA folks who can't get to Ren Faires considering they elected a Queen. And 5% folks who got caught up in the rush and don't know what SCA is \[yet\].

splat-y-chila

I took a peek around and have come to the conclusion that they're all SCA nerds who decided to meet up online because of either COVID or they live too far from the local Ren Faire to actually go in person.

Transman5000

At the end of January, Seelos Therapeutics received a Notice of Appointment from the Japanese Patent Office: The issued patent covers a method of using trehalose (SLS-005) to treat several neurodegenerative conditions including amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, oculopharyngeal muscular dystrophy (OPMD), Huntington's disease, spinocerebellar ataxia (SCA), spinal and bulbar muscular atrophy (SBMA), dentatomral-pailidoluyssan atrophy (DRPLA), Pick's disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), frontotemporal dementia, Parkinson's disease, parkinsonism linked to chromosome 17 (FTDP-17), Alzheimer's disease, and Friedreich ataxia (FA). NEW YORK, Jan. 15, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patients in its registrational Proof of Concept study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder. I think the company has potential to be on the verge of something huge. I am new to investing and wondering if anyone could give me some advice on how to look into whether this is a good buy and/or your opinions on the company.

Transman5000

At the end of January, Seelos Therapeutics received a Notice of Appointment from the Japanese Patent Office: The issued patent covers a method of using trehalose (SLS-005) to treat several neurodegenerative conditions including amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, oculopharyngeal muscular dystrophy (OPMD), Huntington's disease, spinocerebellar ataxia (SCA), spinal and bulbar muscular atrophy (SBMA), dentatomral-pailidoluyssan atrophy (DRPLA), Pick's disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), frontotemporal dementia, Parkinson's disease, parkinsonism linked to chromosome 17 (FTDP-17), Alzheimer's disease, and Friedreich ataxia (FA). NEW YORK, Jan. 15, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patients in its registrational Proof of Concept study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder. I think the company has potential to be on the verge of something huge. I am new to investing and wondering if anyone could give me some advice on how to look into whether this is a good buy and/or your opinions on the company.